Literature DB >> 29133555

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

Sarah M McLeod1, Adam B Shapiro2, Samir H Moussa2, Michele Johnstone3, Robert E McLaughlin3, Boudewijn L M de Jonge3, Alita A Miller2.   

Abstract

The novel diazabicyclooctenone ETX2514 is a potent, broad-spectrum serine β-lactamase inhibitor that restores sulbactam activity against resistant Acinetobacter baumannii The frequency of spontaneous resistance to sulbactam-ETX2514 in clinical isolates was found to be 7.6 × 10-10 to <9.0 × 10-10 at 4× MIC and mapped to residues near the active site of penicillin binding protein 3 (PBP3). Purified mutant PBP3 proteins demonstrated reduced affinity for sulbactam. In a sulbactam-sensitive isolate, resistance also mapped to stringent response genes associated with resistance to PBP2 inhibitors, suggesting that in addition to β-lactamase inhibition, ETX2514 may enhance sulbactam activity in A. baumannii via inhibition of PBP2.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumannii; ETX2514; antibiotic resistance; sulbactam; β-lactamase inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29133555      PMCID: PMC5786785          DOI: 10.1128/AAC.01576-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Continuous fluorescence anisotropy-based assay of BOCILLIN FL penicillin reaction with penicillin binding protein 3.

Authors:  Adam B Shapiro; Rong-Fang Gu; Ning Gao; Stephania Livchak; Jason Thresher
Journal:  Anal Biochem       Date:  2013-04-16       Impact factor: 3.365

2.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

Review 3.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 4.  Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.

Authors:  Anaïs Potron; Laurent Poirel; Patrice Nordmann
Journal:  Int J Antimicrob Agents       Date:  2015-03-24       Impact factor: 5.283

Review 5.  Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.

Authors:  L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2006-09       Impact factor: 8.067

6.  OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Mototsugu Yamada; Kenji Suzuki; Takashi Watanabe; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Mitsuhashi; Takashi Ida; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

7.  Leucine and serine induce mecillinam resistance in Escherichia coli.

Authors:  P Bouloc; D Vinella; R D'Ari
Journal:  Mol Gen Genet       Date:  1992-11

8.  New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.

Authors:  M Doumith; S Mushtaq; D M Livermore; N Woodford
Journal:  J Antimicrob Chemother       Date:  2016-06-20       Impact factor: 5.790

9.  Fluorescence anisotropy-based measurement of Pseudomonas aeruginosa penicillin-binding protein 2 transpeptidase inhibitor acylation rate constants.

Authors:  Adam B Shapiro; Ning Gao; Rong-Fang Gu; Jason Thresher
Journal:  Anal Biochem       Date:  2014-06-16       Impact factor: 3.365

10.  Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.

Authors:  David M Livermore; Marina Warner; Shazad Mushtaq; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

View more
  19 in total

1.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

Review 3.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

4.  Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Robin D Isaacs; John P O'Donnell; Emily Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 5.  Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review.

Authors:  Guido Granata; Fabrizio Taglietti; Francesco Schiavone; Nicola Petrosillo
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

Review 6.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

Review 7.  Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.

Authors:  Focco van den Akker; Robert A Bonomo
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

8.  Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent.

Authors:  Melissa D Barnes; Vijay Kumar; Christopher R Bethel; Samir H Moussa; John O'Donnell; Joseph D Rutter; Caryn E Good; Kristine M Hujer; Andrea M Hujer; Steve H Marshall; Barry N Kreiswirth; Sandra S Richter; Philip N Rather; Michael R Jacobs; Krisztina M Papp-Wallace; Focco van den Akker; Robert A Bonomo
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

9.  A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects.

Authors:  John O'Donnell; Kathleen Maloney; Melissa Steidler; Royce Morrison; Robin Isaacs
Journal:  Clin Transl Sci       Date:  2021-05-02       Impact factor: 4.689

10.  Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.

Authors:  Jason D Lickliter; Kenneth Lawrence; John O'Donnell; Robin Isaacs
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.